Glepaglutide

Drug Profile

Glepaglutide

Alternative Names: ZP 1848

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Zealand Pharma
  • Class Glucagon-like peptides
  • Mechanism of Action Glucagon-like peptide 2 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Short bowel syndrome

Most Recent Events

  • 03 Nov 2015 Phase-II clinical trials in Short bowel syndrome in USA (SC)
  • 17 Sep 2015 Zealand Pharma plans a phase II trial for Short Bowel Syndrome
  • 21 Aug 2014 Suspended - Phase-I for Inflammatory bowel disease in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top